• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SAVA

SAVA

Cassava Sciences, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.32

+0.03 (+2.33%)

Company Profile

CEO

Richard Jon Barry

IPO Date

2000-07-14

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.30

Prev. Close

$1.29

Day Low

$1.27

Day High

$1.34

52W Low

$1.15

52W High

$4.98

Market Cap

$0.06B

Volume

0.13M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

48.9%

Avg Negative

19.4%

Avg Neutral

32.0%

News Feed

Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing

Seeking Alpha·7/30/2021·↑ positive

SAVA Stock Fell 23.61%: Details You Should Know

Pulse2·7/29/2021·↓ negative

Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data

InvestorPlace·7/29/2021·↑ positive

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

The Motley Fool·7/29/2021·↓ negative

Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential

Seeking Alpha·7/27/2021·↑ positive

Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results

InvestorPlace·7/23/2021·↑ positive

An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments

Benzinga·7/23/2021·↑ positive

Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis

Benzinga·7/22/2021·↑ positive

Cassava Sciences stock price forecast for Q3 after shares rally 27%

Invezz·7/21/2021·↑ positive

Here's Why Cassava Sciences Is Surging Today

The Motley Fool·7/21/2021·↑ positive